These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 17875453)

  • 1. Pharmacokinetics and pharmacodynamics of gatifloxacin in children with recurrent otitis media: application of sparse sampling in clinical development.
    Rubino CM; Ambrose P; Cirincione B; Arguedas A; Sher L; Lopez E; Sáez-Llorens X; Grasela DM
    Diagn Microbiol Infect Dis; 2007 Sep; 59(1):67-74. PubMed ID: 17875453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bacteriologic and clinical efficacy of oral gatifloxacin for the treatment of recurrent/nonresponsive acute otitis media: an open label, noncomparative, double tympanocentesis study.
    Leibovitz E; Piglansky L; Raiz S; Greenberg D; Hamed KA; Ledeine JM; Press J; Leiberman A; Echols RM; Pierce PF; Jacobs MR; Dagan R
    Pediatr Infect Dis J; 2003 Nov; 22(11):943-9. PubMed ID: 14614364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, investigator-blinded, multicenter, comparative study of gatifloxacin versus amoxicillin/clavulanate in recurrent otitis media and acute otitis media treatment failure in children.
    Sher L; Arguedas A; Husseman M; Pichichero M; Hamed KA; Biswas D; Pierce P; Echols R
    Pediatr Infect Dis J; 2005 Apr; 24(4):301-8. PubMed ID: 15818288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Open label, multicenter study of gatifloxacin treatment of recurrent otitis media and acute otitis media treatment failure.
    Arguedas A; Sher L; Lopez E; Sáez-Llorens X; Hamed K; Skuba K; Pierce PF
    Pediatr Infect Dis J; 2003 Nov; 22(11):949-56. PubMed ID: 14614365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections.
    Ambrose PG; Grasela DM; Grasela TH; Passarell J; Mayer HB; Pierce PF
    Antimicrob Agents Chemother; 2001 Oct; 45(10):2793-7. PubMed ID: 11557471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of gatifloxacin pharmacokinetics and pharmacodynamics in severely ill adults in a medical Intensive Care Unit.
    Fish DN
    Int J Antimicrob Agents; 2007 Jun; 29(6):715-23. PubMed ID: 17433631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cefdinir pharmacokinetics and tolerability in children receiving 25 mg/kg once daily.
    Bowlware KL; McCracken GH; Lozano-Hernandez J; Ghaffar F
    Pediatr Infect Dis J; 2006 Mar; 25(3):208-10. PubMed ID: 16511381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of gatifloxacin and levofloxacin administered at various dosing regimens to hospitalised patients with community-acquired pneumonia: pharmacodynamic target attainment study using North American surveillance data for Streptococcus pneumoniae.
    Noreddin AM; Hoban DJ; Zhanel GG
    Int J Antimicrob Agents; 2005 Aug; 26(2):120-5. PubMed ID: 16046101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of gatifloxacin therapy for children with recurrent acute otitis media (AOM) and/or AOM treatment failure.
    Pichichero ME; Arguedas A; Dagan R; Sher L; Saez-Llorens X; Hamed K; Echols R
    Clin Infect Dis; 2005 Aug; 41(4):470-8. PubMed ID: 16028153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential role of fluoroquinolone therapy in childhood otitis media.
    Dagan R; Arguedas A; Schaad UB
    Pediatr Infect Dis J; 2004 May; 23(5):390-8. PubMed ID: 15131460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamic assessment of gatifloxacin against Streptococcus pneumoniae.
    Mattoes HM; Banevicius M; Li D; Turley C; Xuan D; Nightingale CH; Nicolau DP
    Antimicrob Agents Chemother; 2001 Jul; 45(7):2092-7. PubMed ID: 11408228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicenter, open label, double tympanocentesis study of high dose cefdinir in children with acute otitis media at high risk of persistent or recurrent infection.
    Arguedas A; Dagan R; Leibovitz E; Hoberman A; Pichichero M; Paris M
    Pediatr Infect Dis J; 2006 Mar; 25(3):211-8. PubMed ID: 16511382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo pharmacodynamic efficacy of gatifloxacin against Streptococcus pneumoniae in an experimental model of pneumonia: impact of the low levels of fluoroquinolone resistance on the enrichment of resistant mutants.
    Croisier D; Etienne M; Piroth L; Bergoin E; Lequeu C; Portier H; Chavanet P
    J Antimicrob Chemother; 2004 Sep; 54(3):640-7. PubMed ID: 15317743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gatifloxacin and the elderly: pharmacokinetic-pharmacodynamic rationale for a potential age-related dose reduction.
    Ambrose PG; Bhavnani SM; Cirincione BB; Piedmonte M; Grasela TH
    J Antimicrob Chemother; 2003 Sep; 52(3):435-40. PubMed ID: 12917247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics-pharmacodynamics of gatifloxacin in a lethal murine Bacillus anthracis inhalation infection model.
    Ambrose PG; Forrest A; Craig WA; Rubino CM; Bhavnani SM; Drusano GL; Heine HS
    Antimicrob Agents Chemother; 2007 Dec; 51(12):4351-5. PubMed ID: 17875992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of gatifloxacin tested against isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (North America, 1998-2003).
    Fedler KA; Jones RN; Sader HS; Fritsche TR
    Diagn Microbiol Infect Dis; 2006 Jun; 55(2):157-64. PubMed ID: 16529904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections.
    Van Wart S; Phillips L; Ludwig EA; Russo R; Gajjar DA; Bello A; Ambrose PG; Costanzo C; Grasela TH; Echols R; Grasela DM
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4766-77. PubMed ID: 15561855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamic analysis of ceftriaxone, gatifloxacin,and levofloxacin against Streptococcus pneumoniae with the use of Monte Carlo simulation.
    Frei CR; Burgess DS
    Pharmacotherapy; 2005 Sep; 25(9):1161-7. PubMed ID: 16164390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamics of gatifloxacin in experimental models of pneumococcal meningitis.
    McCracken GH
    Clin Infect Dis; 2000 Aug; 31 Suppl 2():S45-50. PubMed ID: 10984328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of vitreous levels of gatifloxacin after systemic administration in inflamed and non-inflamed eyes.
    Rajpal ; Srinivas A; Azad RV; Sharma YR; Kumar A; Satpathy G; Velpandian T
    Acta Ophthalmol; 2009 Sep; 87(6):648-52. PubMed ID: 19508273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.